
|Podcasts|October 15, 2021
Targeting KRAS Mutations in Gastrointestinal Oncology
Author(s)Lindsay Fischer
“Previously, this mutation has been undruggable, but this is now changing.”
Advertisement
For this episode of “The Vitals,” we spoke with Kristin Barber, FNP-BC, AOCNP, Huntsman Cancer Institute, about understanding the MAP kinase signaling pathway and some of the ongoing trials targeting these mutations in gastrointestinal oncology.
Barber discussed some of the ongoing phase 1 trials she is participating in and how she hopes the results of these trials could change patient outcomes following targeted treatment.
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Opinion: CAR T-Cell Therapy Shows Promise in Gastric and GEJ Cancers
2
Real, Placebo Acupuncture Improve Cognitive Outcomes in Breast Cancer Survivors
3
FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications
4
FDA Approves Rucaparib in BRCA-Mutated Metastatic CRPC
5




















































































